用于塞拉利昂埃博拉疫苗整群随机3期试验设计的实时动态建模
在2013-16年西非埃博拉病毒病(EVD)疫情末期,发病率下降和空间异质性使3期疫苗试验设计困难。研究实时拟合、预测并模拟了塞拉利昂三个候选地区针对初免-加强EVD疫苗的3期整群随机试验,旨在预测试验可行性并指导设计规划。结果显示EVD发病率波动大,试验启动延迟会大幅降低检测效果的能力,实时模型更新有助于决策者判断试验可行性随时间的变化。
要点
- EVD发病率在疫情下降期高度变异,试验启动延迟会大幅降低检测效果的能力。
- 有效疫苗会使疫苗组疫情更快消失,进一步影响效果评估。
- 实时动态传播模型可同时模拟效果和效力,有助于选择试验地点和评估可行性。
核心结论
- 该分析通过动态传播模型同时模拟效力和效果,有助于疫苗试验规划,并对试验地点选择和可行性决策作出贡献。
- 传播模型应尽早用于设计过程,以提供预期发病率的机制性估计,据此决定样本量、地点、时机和可行性。
研究设计与样本
- 实时拟合、预测并模拟了塞拉利昂三个候选地区针对初免-加强EVD疫苗的3期整群随机试验,以预测试验可行性并指导设计规划。
主要发现
- EVD发病率在疫情期间高度变异,尤其在下降阶段。
- 试验启动日期的延迟预计会大幅降低检测效果的能力,尤其因为有效疫苗会使疫苗组疫情更快消失。
- 模型的实时更新使决策者能够确定试验可行性随时间的变化。
临床怎么用
- 作者认为,传播模型应尽早用于设计过程,以提供预期发病率的机制性估计,据此决定样本量、地点、时机和可行性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013-16 Ebola virus disease (EVD) epidemic in West Africa. Mathematical models can provide forecasts of expected incidence through time and can account for both vaccine efficacy in participants and effectiveness in populations. Determining expected disease incidence was critical to calculating power and determining trial sample size. METHODS: In real-time, we fitted, forecasted, and simulated a proposed phase 3 cluster-randomized vaccine trial for a prime-boost EVD vaccine in three candidate regions in Sierra Leone. The aim was to forecast trial feasibility in these areas through time and guide study design planning. RESULTS: EVD incidence was highly variable during the epidemic, especially in the declining phase. Delays in trial start date were expected to greatly reduce the ability to discern an effect, particularly as a trial with an effective vaccine would cause the epidemic to go extinct more quickly in the vaccine arm. Real-time updates of the model allowed decision-makers to determine how trial feasibility changed with time. CONCLUSIONS: This analysis was useful for vaccine trial planning because we simulated effectiveness as well as efficacy, which is possible with a dynamic transmission model. It contributed to decisions on choice of trial location and feasibility of the trial. Transmission models should be utilised as early as possible in the design process to provide mechanistic estimates of expected incidence, with which decisions about sample size, location, timing, and feasibility can be determined.
引用
- Camacho A, Eggo RM, Goeyvaerts N, et al. Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone. Vaccine. 2016. PMID: 28024952. doi:10.1016/j.vaccine.2016.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。